Key Takeaways
- • TailorMed announced it has secured a majority private equity investment from New York-based GrowthCurve Capital, according to the company's announcement as reported by HIT Consultant.
- • GrowthCurve Capital focuses on accelerating middle-market technology enterprises through operationalizing artificial intelligence, product engineering, and proprietary datasets.
- • TailorMed reports its platform is integrated across more than 950 hospitals, 4,700 outpatient clinics, and 3,100 pharmacies nationwide, and has supported over 75 million patients since 2020.
- • The platform has unlocked more than $7.4 billion in financial assistance and maps into more than 6,000 public and private assistance programs and over 100 life sciences patient support initiatives.
- • The capital is intended to scale the company's AI-enabled software portfolio and address financial toxicity and therapy drop-off in complex oncology, rare disease, and chronic specialty cohorts.
Summary
TailorMed, a medication access and financial assistance technology company, announced that it has secured a majority private equity investment from GrowthCurve Capital, a New York-based firm. The source material does not disclose the transaction value or the ownership stake acquired.
According to the announcement, GrowthCurve focuses on accelerating middle-market technology enterprises by operationalizing artificial intelligence, product engineering, and unlocking proprietary datasets. The company said the transaction positions TailorMed to scale its AI-enabled software portfolio and expand distribution across hospital health systems, ambulatory clinics, retail and specialty pharmacies, and life sciences manufacturers.
TailorMed was founded in 2016 by Srulik Dvorsky and Adam Siton, and evolved from a niche financial navigation software into what it describes as a unified medication access operating system. The company says its defensibility rests on multi-sided network density that bridges clinical EHR charting, pharmacy dispensing queues, and manufacturer affordability programs. It reports integration across more than 950 hospitals, 4,700 outpatient clinics and 3,100 pharmacies nationwide, and says it has supported more than 75 million patients and unlocked more than $7.4 billion in financial assistance since 2020.
The platform's five product layers include TailorMed Core, which identifies at-risk patients early in the clinical encounter by predicting out-of-pocket exposure; TailorMed Connect & Complete, which automates enrollment for foundation grants, co-pay assistance, government subsidies and free drug programs; and TailorMed Amplify & Alliance, which routes manufacturer copay cards and patient support services into EHR-integrated workflows.
CEO and Co-Founder Srulik Dvorsky said the company set out to address affordability barriers that prevent patients from accessing prescribed medications, and described GrowthCurve as sharing the company's mission while bringing the experience and strategic support needed to expand across the medication lifecycle.
According to the announcement, GrowthCurve focuses on accelerating middle-market technology enterprises by operationalizing artificial intelligence, product engineering, and unlocking proprietary datasets. The company said the transaction positions TailorMed to scale its AI-enabled software portfolio and expand distribution across hospital health systems, ambulatory clinics, retail and specialty pharmacies, and life sciences manufacturers.
TailorMed was founded in 2016 by Srulik Dvorsky and Adam Siton, and evolved from a niche financial navigation software into what it describes as a unified medication access operating system. The company says its defensibility rests on multi-sided network density that bridges clinical EHR charting, pharmacy dispensing queues, and manufacturer affordability programs. It reports integration across more than 950 hospitals, 4,700 outpatient clinics and 3,100 pharmacies nationwide, and says it has supported more than 75 million patients and unlocked more than $7.4 billion in financial assistance since 2020.
The platform's five product layers include TailorMed Core, which identifies at-risk patients early in the clinical encounter by predicting out-of-pocket exposure; TailorMed Connect & Complete, which automates enrollment for foundation grants, co-pay assistance, government subsidies and free drug programs; and TailorMed Amplify & Alliance, which routes manufacturer copay cards and patient support services into EHR-integrated workflows.
CEO and Co-Founder Srulik Dvorsky said the company set out to address affordability barriers that prevent patients from accessing prescribed medications, and described GrowthCurve as sharing the company's mission while bringing the experience and strategic support needed to expand across the medication lifecycle.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.